Latest From Ian Lloyd
Infographic examines the current status of biopharma pipelines by trial phase, company, and therapeutic areas.
GlaxoSmithKline (GSK) has regained the crown of for the most drugs in development by a pharma company after two years of being displaced by Pfizer, despite reporting a small drop in the number of its R&D products.
A decade ago, the publication of the human genome foreshadowed an explosion in new drug targets. Those predictions now seem to have been overly optimistic.
At last, some signs that the pharma industry is addressing attrition in the late-stage pipeline – with the biggest annual rise in Phase III products on record.
The drop in pipeline cancer compounds in 2009 turned out to be a temporary blip.
No surprises in the top 10, but the number of smaller companies involved in R&D, including a wealth of start-ups, continues on its unrelenting growth trajectory.